1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Branded Generics Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Branded Generics Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Rising Adoption of Branded Generics owing to their Affordability to Favor Market
- 5.1.2 Spurring government initiatives for the development of branded generics augmenting the market growth
5.2 Market Opportunities
- 5.2.1 Loss of Patent Exclusivity of Branded drugs and Emergence of Biosimilars Brings Future Opportunities
5.3 Future Trends
- 5.3.1 Utilization of Branded Generics by Healthcare Providers and Professionals
5.4 Impact of Drivers and Restraints
6. Europe Branded Generics Market Regional Analysis
6.1 Europe Branded Generics Market Overview
6.2 Europe Branded Generics Market Revenue 2020-2028 (US$ Billion)
6.3 Europe Branded Generics Market Forecast Analysis
7. Europe Branded Generics Market Analysis – by Therapeutic Application
7.1 Oncology
- 7.1.1 Overview
- 7.1.2 Oncology: Europe Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.2 Cardiovascular Diseases
- 7.2.1 Overview
- 7.2.2 Cardiovascular Diseases: Europe Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.3 Diabetes
- 7.3.1 Overview
- 7.3.2 Diabetes: Europe Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.4 Neurology
- 7.4.1 Overview
- 7.4.2 Neurology: Europe Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.5 Gastrointestinal Diseases
- 7.5.1 Overview
- 7.5.2 Gastrointestinal Diseases: Europe Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.6 Dermatology Diseases
- 7.6.1 Overview
- 7.6.2 Dermatology Diseases: Europe Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
7.7 Analgesics and Anti-Inflammatory
- 7.7.1 Overview
- 7.7.2 Analgesics and Anti-Inflammatory: Europe Branded Generics Market – Revenue and Forecast to 2031 (US$ Billion)
8. Europe Branded Generics Market Analysis – by Distribution Channel
8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Hospitals: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.2 Retail Pharmacies
- 8.2.1 Overview
- 8.2.2 Retail Pharmacies: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.3 Online Pharmacies
- 8.3.1 Overview
- 8.3.2 Online Pharmacies: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.4 Drug Stores
- 8.4.1 Overview
- 8.4.2 Drug Stores: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9. Europe Branded Generics Market Analysis – by Drug Class
9.1 Alkylating Agents
- 9.1.1 Overview
- 9.1.2 Drug Stores: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.2 Antimetabolites
- 9.2.1 Overview
- 9.2.2 Drug Stores: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.3 Hormones
- 9.3.1 Overview
- 9.3.2 Drug Stores: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.4 Antihypertensive
- 9.4.1 Overview
- 9.4.2 Drug Stores: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.5 Lipid-Lowering Drugs
- 9.5.1 Overview
- 9.5.2 Drug Stores: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.6 Antidepressants
- 9.6.1 Overview
- 9.6.2 Drug Stores: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.7 Antipsychotics
- 9.7.1 Overview
- 9.7.2 Drug Stores: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.8 Antiepileptic
- 9.8.1 Overview
- 9.8.2 Drug Stores: Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
10. Europe Branded Generics Market – Europe Analysis
10.1 Europe
- 10.1.1 Europe Branded Generics Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 10.1.1.1 Europe Branded Generics Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 UK:
Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
- 10.1.1.1.1 UK: Europe Branded Generics Market Breakdown, by Therapeutic Application
- 10.1.1.1.2 UK: Europe Branded Generics Market Breakdown, by Distribution Channel
- 10.1.1.1.3 UK: Europe Branded Generics Market Breakdown, by Drug Class
- 10.1.1.2 Germany:
Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
- 10.1.1.2.1 Germany: Europe Branded Generics Market Breakdown, by Therapeutic Application
- 10.1.1.2.2 Germany: Europe Branded Generics Market Breakdown, by Distribution Channel
- 10.1.1.2.3 Germany: Europe Branded Generics Market Breakdown, by Drug Class
- 10.1.1.3 France:
Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
- 10.1.1.3.1 France: Europe Branded Generics Market Breakdown, by Therapeutic Application
- 10.1.1.3.2 France: Europe Branded Generics Market Breakdown, by Distribution Channel
- 10.1.1.3.3 France: Europe Branded Generics Market Breakdown, by Drug Class
- 10.1.1.4 Russia:
Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
- 10.1.1.4.1 Russia: Europe Branded Generics Market Breakdown, by Therapeutic Application
- 10.1.1.4.2 Russia: Europe Branded Generics Market Breakdown, by Distribution Channel
- 10.1.1.4.3 Russia: Europe Branded Generics Market Breakdown, by Drug Class
- 10.1.1.5 Italy:
Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
- 10.1.1.5.1 Italy: Europe Branded Generics Market Breakdown, by Therapeutic Application
- 10.1.1.5.2 Italy: Europe Branded Generics Market Breakdown, by Distribution Channel
- 10.1.1.5.3 Italy: Europe Branded Generics Market Breakdown, by Drug Class
- 10.1.1.6 Rest of Europe:
Europe Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
- 10.1.1.6.1 Rest of Europe: Europe Branded Generics Market Breakdown, by Therapeutic Application
- 10.1.1.6.2 Rest of Europe: Europe Branded Generics Market Breakdown, by Distribution Channel
- 10.1.1.6.3 Rest of Europe: Europe Branded Generics Market Breakdown, by Drug Class
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Europe Branded Generics Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Aspen Holdings
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 AstraZeneca
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Bausch Health (Valeant Pharmaceuticals)
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Dr. Reddy's Laboratories Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 GlaxoSmithKline plc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Hetero
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Lupin
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 MYLAN N.V.
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Par Pharmaceuticals
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Sandoz International Gmbh
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Sanofi
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
13.12 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 13.12.1 Key Facts
- 13.12.2 Business Description
- 13.12.3 Products and Services
- 13.12.4 Financial Overview
- 13.12.5 SWOT Analysis
- 13.12.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For Europe Branded Generics Market
